[Treatment and prevention of osteoporosis in patients with decreased renal function].
Decreased renal function and osteoporosis are both frequent conditions in the general population. Most drugs for treating osteoporosis seem safe for patients with mildly decreased renal function (glomerular filtration rate [GFR] 60-90 ml/min). In patients with a moderately decreased GFR of 30-60 ml/min, there are very few studies with BMD as endpoint. Most drugs seem safe in terms of affecting renal function. The aim should be to control calcium and vitamin D metabolism in patients with severely decreased renal function (GFR<30 ml/min) or on dialysis.
Vestergaard
Peter
P
Aalborg Sygehus, Endokrinologisk Afdeling, Aalborg. p-vest@post4.tele.dk
Eiken
Pia A
PA
D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002118:Calcium / Q000378:metabolism; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control; D006435:Renal Dialysis; D051437:Renal Insufficiency / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014807:Vitamin D / Q000378:metabolism
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D020845:Selective Estrogen Receptor Modulators; D014807:Vitamin D; D002118:Calcium